'Carnage, Plain And Simple': Supreme Court Flags Rs 27,000 MRP On Rs 3,000 Cancer Drug
NDTV Profit 1 hr ago·29 Sept 2026, 10:55 am
Supreme Court flagged that a cancer drug sold under a government health scheme carries a maximum retail price of Rs 27,000 while its production cost is roughly Rs 3,000, highlighting a large gap between cost and price and questioning hospital and pharmacy pricing practices.
For investors, the ruling points to possible regulatory pressure on drug pricing, especially for firms that set high MRPs on essential medicines. A mandated price reduction could squeeze margins and affect revenue expectations for companies linked to the drug.
Market watchers should keep an eye on any further court orders, revisions to the drug’s price, and broader policy debates about price caps under the health scheme, as these developments could influence future profitability and pricing strategies.
Affected stocks
Bearish1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns MRP Agro (MRP).
- Category: Economy.
- AI reads the tone as negative (potentially bearish) for the stock.
- Flagged as a high-impact, market-moving story.
Why it matters
This is a high-impact development for MRP Agro and could move the stock. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.
